Abstract
Rituximab, a humanized monoclonal antibody approved for malignant lymphoma, is being increasingly, effectively, and safely used for immune thrombocytopenic purpura (ITP) and other humoral autoimmune disorders. We report the case of a 43-year-old man with ITP refractory to steroids and intravenous immunoglobulin who developed acute respiratory distress syndrome (ARDS) after a single infusion of rituximab. Dyspnea, hypoxemia, and pleuritic chest pain occurred within 24 hours of rituximab administration, and there was no other apparent explanation. Progressive hypoxemia mandated endotracheal intubation 1 week after rituximab administration and led to death 4 weeks after admission. ARDS has been associated with the administration of other monoclonal antibodies, such as infliximab, gemtuzumab ozogamicin, and OKT3 and is believed to be directly mediated by release of proinflammatory cytokines. ARDS is rarely associated with rituximab infusion for lymphoproliferative disorders, but it should be considered by those administering rituximab, especially when a patient develops severe pulmonary symptoms soon after infusion.
Article PDF
Similar content being viewed by others
References
Dillman RO. Magic bullets at last! Finally-approval of a monoclonal antibody for the treatment of cancer!Cancer Biother Radio-pharm. 1997;12:223–225.
Cooper N, Stasi R, Cunningham-Rundles S, et al. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura.Br J Haematol. 2004;125:232–239.
Stasi R, Pagano A, Stipa E, Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idio-pathic thrombocytopenic purpura.Blood. 2001;98:952–927.
Bussel JB. Fc receptor blockade and immune thrombocytopenic purpura.Semin Hematol. 2000;37:261–266.
Kojouri K, George JN. Recent advances in the treatment of chronic refractory immune thrombocytopenic purpura.Int J Hematol. 2005;81:119–125.
Dillman RO. Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy.Cancer Metastasis Rev. 1999;18:465–471.
Saito B, Nakamaki T, Adachi D, Suzuki J, Tomoyasu S. Acute respiratory distress syndrome during the third infusion of rituximab in a patient with follicular lymphoma.IntJ Hematol. 2004;80:164–167.
Byrd JC, Waselenko JK, Maneatis TJ, et al. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance.J Clin Oncol. 1999;17:791–795.
Burton C, Kaczmarski R, Jan-Mohamed R. Interstitial pneumonitis related to rituximab therapy.N Engl J Med. 2003;348:2690–2691.
Hiraga J, Kondoh Y, Taniguchi H, Kinoshita T, Naoe T. A case of interstitial pneumonia induced by rituximab therapy.Int J Hematol. 2005;81:169–170.
Jullien V, Perrin C, Peyrade F, Lemoigne F, Chichmanian RM, Blaive B. Alveolar hypoxemic interstitial pneumonia related to rituximab therapy [in French].Rev Mal Respir. 2004;21:407–410.
Swords R, Power D, Fay M, O’Donnell R, Murphy PT. Interstitial pneumonitis following rituximab therapy for immune thrombocytopenic purpura (ITP).Am J Hematol. 2004;77:103–104.
Ware LB, Matthay MA. The acute respiratory distress syndrome.N Engl J Med. 2000;342:1334–1349.
Frey DJ, Matas AJ, Gillingham KJ, et al. Sequential therapy: a prospective randomized trial of MALG versus OKT3 for prophylactic immunosuppression in cadaver renal allograft recipients.Transplantation. 1992;54:50–56.
Bamgbola FO, Del Rio M, Kaskel FJ, Flynn JT. Non-cardiogenic pulmonary edema during basiliximab induction in three adolescent renal transplant patients.Pediatr Transplant. 2003;7:315–320.
Bross PF, Beitz J, Chen G, et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.Clin Cancer Res. 2001;7:1490–1496.
Riegert-Johnson DL, Godfrey JA, Myers JL, Hubmayr RD, Sandborn WJ, Loftus EV Jr. Delayed hypersensitivity reaction and acute respiratory distress syndrome following infliximab infusion.Inflamm Bowel Dis. 2002;8:186–191.
Herceptin (trastuzumab) [package insert]. South San Francisco, CA:Genentech; 2005.
Porterfield LM. Did a monoclonal antibody cause this patient’s death?RN. 2000;63:119.
Vallhonrat H, Williams WW, Cosimi AB, et al. In vivo generation of C4d, Bb, iC3b, and SC5b-9 after OKT3 administration in kidney and lung transplant recipients.Transplantation. 1999;67:253–258.
Charpentier B, Hiesse C, Ferran C, et al. Acute clinical syndrome associated with OKT3 administration: prevention by single injection of an anti-human TNF monoclonal antibody [in French].Presse Med. 1991;20:2009–2011.
Charpentier B, Hiesse C, Lantz O, et al. Evidence that antihuman tumor necrosis factor monoclonal antibody prevents OKT3-induced acute syndrome.Transplantation. 1992;54:997–1002.
Hanauer SB. Review article: safety of infliximab in clinical trials.Aliment Pharmacol Ther. 1999;13(suppl 4):16–22.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Montero, A.J., McCarthy, J.J., Chen, G. et al. Acute Respiratory Distress Syndrome after Rituximab Infusion. Int J Hematol 82, 324–326 (2005). https://doi.org/10.1532/IJH97.NA0506
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1532/IJH97.NA0506